Influenza News and Research

Latest Influenza News and Research

Aethlon Medical reestablishes efforts to advance Aethlon Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it has reestablished efforts to advance the Aethlon Hemopurifier within U.S. Government programs that support the development and purchase of treatment countermeasures against bioterror threats.

21 Sep 2010

Researchers to develop vaccine for plague

Given the many pressing concerns of the day, fear of plague probably isn't what causes most Americans to lose sleep. But for those whose responsibility it is to combat bioterrorism, plague is among the highest priorities. Those charged with that mission include scientists like medical researcher Steve Smiley, whose lab at the Trudeau Institute is working to develop a vaccine that will protect the public against weaponized forms of plague.

21 Sep 2010

Inovio Pharmaceuticals completes enrollment for PENNVAX-B vaccine Phase I clinical study

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the Phase I clinical study assessing Inovio's PENNVAX-B DNA vaccine delivered using its proprietary electroporation technology in a preventive setting has fully completed the enrollment of 48 healthy volunteers. The multi-center study is being conducted by Inovio's clinical collaborator, the HIV Vaccine Trials Network (HVTN), at several clinical sites under a protocol designated HVTN-080.

21 Sep 2010

Scientists identify new pathway to control immune balance

St. Jude Children's Research Hospital scientists have identified a new pathway that helps control the immune balance through reciprocal regulation of specialized T lymphocytes, which play very different inflammatory roles.

21 Sep 2010

Flu shots, heart attacks and flu prevention guidelines

According to a new British study yearly flu shots may protect against heart attacks, and the earlier in the season a shot is given the greater the protection. Niroshan Siriwardena, a professor of primary and pre-hospital health care at the University of Lincoln said, “The risk of getting a heart attack was reduced by 19 percent for those who had a vaccination in the past year.”

21 Sep 2010

Six3 gene safeguards future retina

New research led by St. Jude Children's Research Hospital investigators adds to evidence that the Six3 gene functions like a doorman in the developing brain and visual system, safeguarding the future retina by keeping the region where the eye is forming free of a signaling protein capable of disrupting the process.

21 Sep 2010

AstraZeneca urges to increase funds for FDA fiscal year 2012 budget

AstraZeneca urged the Obama Administration to increase funding for the Food and Drug Administration's fiscal year 2012 budget by 20 percent to help the agency effectively manage a growing list of complex public health responsibilities.

21 Sep 2010

H1N1 influenza increases neurological complications in children: Study

A recent study by researchers at the University of Utah determined that the 2009 pandemic influenza A (H1N1) caused a higher rate of neurological complications in children than the seasonal flu. The most common complications observed were seizures and encephalopathy.

20 Sep 2010

Johnson & Johnson in talks to buy Crucell

Johnson & Johnson is in advanced negotiations to buy Dutch biotechnology company Crucell NV for €1.75 billion ($2.29 billion), the two companies said today. Giles Somers, senior healthcare analyst at Datamonitor comments:

19 Sep 2010

CytoGenix initiates novel liner DNA technology testing on ferrets for vaccine development

CytoGenix, Inc. today announced that it has initiated the process of testing CytoGenix's novel liner DNA technology on ferrets, with the expectations of a positive result, furthering the development of the vaccine candidate.

18 Sep 2010

CMB initiates first human trial for plant-produced H1N1 influenza vaccine

Fraunhofer USA Center for Molecular Biotechnology (CMB) announced today it has initiated the first human trial of plant-produced H1N1 influenza vaccine at the Walter Reed Army Institute of Research Clinical Trials Center (WRAIR-CTC).

18 Sep 2010

BARDA awards contract to Emergent BioSolutions for anthrax vaccine development

The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) awarded a $51 million contract to Emergent BioSolutions, Inc., of Rockville, Md., for the development of a new anthrax vaccine using the protective antigen (rPA) to stimulate a protective immune response that neutralizes the anthrax toxins.

18 Sep 2010

Johnson & Johnson, Crucell announce advanced negotiations for potential public offer

Johnson & Johnson and Crucell N.V. today announced that they are in advanced negotiations for a potential public offer by Johnson & Johnson or an affiliate for all outstanding ordinary shares of Crucell not already held by Johnson & Johnson and its affiliates.

17 Sep 2010

Generex presents Ii-Key hybrids product development at Gene based Vaccines conference

Generex Biotechnology Corporation today announced presentations in respect of the technologies and development products of its wholly-owned subsidiary, Antigen Express, Inc. The presentations were made at the conference Gene based Vaccines: Optimizing Development and Delivery 2010 held September 13 and 14, 2010 in Vienna, Austria and at the Immunotherapeutics and Vaccine Summit held in Cambridge, MA from August 17-19, 2010.

17 Sep 2010

LigoCyte to enroll 98 subjects in first clinical trial for bivalent IM norovirus vaccine

LigoCyte Pharmaceuticals, Inc., a private, clinical-stage biopharmaceuticals company focused on the development of innovative vaccine products, announced today that it has initiated the first clinical trial for its bivalent intramuscular (IM) norovirus vaccine candidate, marking the fourth human clinical trial in the Company's norovirus virus-like particle (VLP) vaccine program.

17 Sep 2010

NovaBay Pharmaceuticals delivers poster presentations on Aganocide compound at ICAAC Conference

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic resistant infections, delivered four poster presentations on its Aganocide compounds at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, MA.

16 Sep 2010

Friendship paradox helps analyze social network, monitor member health to predict flu outbreak

Nicholas Christakis, professor of medicine, medical sociology and sociology at Harvard University, and James Fowler, professor of medical genetics and political science at the University of California, San Diego, used the paradox to study the 2009 flu epidemic among 744 students. The findings, the researchers say, point to a novel method for early detection of contagious outbreaks.

16 Sep 2010

BioCryst Pharmaceuticals announces BCX4208 compound results for treating gout

BioCryst Pharmaceuticals, Inc. announced positive top-line results from its randomized, double-blind, multi-center, placebo-controlled Phase 2 study designed to evaluate the urate-lowering activity and safety of several doses of BCX4208 alone and in combination with selected doses of allopurinol administered once-daily.

16 Sep 2010

Researchers investigate antimicrobial activity of Aganocide compounds against H1N1

Fears over the influenza A virus (H1N1; sometimes referred to as swine flu) have motivated researchers to investigate the antimicrobial activity of the Aganocide compounds against viruses. In a study presented at this year's Interscience Conference on Antimicrobial Agents and Chemotherapy, a team led by Professor Markus Nagl, MD of Medical University of Innsbruck and including D. Debabov, PhD and K. Hybiske, PhD of NovaBay Pharmaceuticals evaluated the in vitro virucidal activity of three compounds: N-chlorotaurine, a compound produced by human phagocytes; and two NCT analogs, NVC-612 and NVC-422.

16 Sep 2010

Doctors demonstrate the true impact of vaccination

With Children Back in School, Doctors Clear up Confusion and Demonstrate the True Impact of Vaccination

16 Sep 2010

Influenza News and Research

Latest Influenza News and Research

Aethlon Medical reestablishes efforts to advance Aethlon Hemopurifier

Researchers to develop vaccine for plague

Inovio Pharmaceuticals completes enrollment for PENNVAX-B vaccine Phase I clinical study

Scientists identify new pathway to control immune balance

Flu shots, heart attacks and flu prevention guidelines

Six3 gene safeguards future retina

AstraZeneca urges to increase funds for FDA fiscal year 2012 budget

H1N1 influenza increases neurological complications in children: Study

Johnson & Johnson in talks to buy Crucell

CytoGenix initiates novel liner DNA technology testing on ferrets for vaccine development

CMB initiates first human trial for plant-produced H1N1 influenza vaccine

BARDA awards contract to Emergent BioSolutions for anthrax vaccine development

Johnson & Johnson, Crucell announce advanced negotiations for potential public offer

Generex presents Ii-Key hybrids product development at Gene based Vaccines conference

LigoCyte to enroll 98 subjects in first clinical trial for bivalent IM norovirus vaccine

NovaBay Pharmaceuticals delivers poster presentations on Aganocide compound at ICAAC Conference

Friendship paradox helps analyze social network, monitor member health to predict flu outbreak

BioCryst Pharmaceuticals announces BCX4208 compound results for treating gout

Researchers investigate antimicrobial activity of Aganocide compounds against H1N1

Doctors demonstrate the true impact of vaccination

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Influenza News and Research

Latest Influenza News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in